ImmunoCellular’s Stem-to-T-Cell technology is designed to stimulate the patient’s immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects.
At the end of 2017, the research team at ImmunoCellular successfully transfected genetic material into human hematopoietic stem cells. That work was the basis for a next key milestone in the program, namely, verification of successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells. This milestone represents the next important step in validating the Stem-to-T-Cell approach, and is a key component of the proof-of-concept work for this technology.
Successful completion of this phase of work enables the Company to begin preclinical testing in animals, which, if successful, could allow ImmunoCellular’s Stem-to-T-Cell technology to advance into human clinical testing.
ImmunoCellular and its collaborators are now working to design and implement the necessary animal studies to complete our proof-of-concept work. The Company’s vision is to develop solutions for intractable cancers, extend the lives of cancer patients, and provide hope for a potential cure. The Company believes that its Stem-to-T-Cell program is potentially a game-changing treatment for cancer, and could be effective in treating many types of cancers.